Biohaven Ltd BHVN:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
40.69UNCH (UNCH)
Volume
27,160
Close
40.69quote price arrow up+0.79 (+1.98%)
Volume
755,775
52 week range
13.03 - 62.21
Loading...
  • Open40.72
  • Day High42.10
  • Day Low40.45
  • Prev Close39.90
  • 52 Week High62.21
  • 52 Week High Date03/08/24
  • 52 Week Low13.03
  • 52 Week Low Date05/04/23

Key Stats

  • Market Cap3.591B
  • Shares Out88.26M
  • 10 Day Average Volume1.51M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-4.93

KEY STATS

  • Open40.72
  • Day High42.10
  • Day Low40.45
  • Prev Close39.90
  • 52 Week High62.21
  • 52 Week High Date03/08/24
  • 52 Week Low13.03
  • 52 Week Low Date05/04/23
  • Market Cap3.591B
  • Shares Out88.26M
  • 10 Day Average Volume1.51M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-4.93

RATIOS/PROFITABILITY

  • EPS (TTM)-5.67
  • P/E (TTM)-7.18
  • Fwd P/E (NTM)-6.63
  • EBITDA (TTM)-429.139M
  • ROE (TTM)-84.44%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Biohaven Ltd

 

Profile

MORE
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and...
Vlad Coric M.D.
Chairman of the Board, Chief Executive Officer
Matthew Buten
Chief Financial Officer
Address
215 Church Street
New Haven, CT
06510
United States

Top Peers

SYMBOLLASTCHG%CHG
SWTX
SpringWorks Therapeutics Inc
45.11+1.76+4.06%
CRNX
Crinetics Pharmaceuticals Inc
47.20+0.42+0.90%
IOVA
Iovance Biotherapeutics Inc
13.63+0.75+5.82%
XENE
Xenon Pharmaceuticals Inc
43.75+0.75+1.74%
JANX
Janux Therapeutics Inc
64.78+2.35+3.76%